Ranbaxy Disappointed By U.S. FDA’s Warning Letters And “Import Alert”

MUMBAI - India's largest drug maker Ranbaxy expressed its disappointment over U.S. FDA's move to issue warning letters and import alerts against drug products manufactured at its sites in Dewas in Madhya Pradesh and Paonta Sahib in Himachal Pradesh